Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The role of glucagon-like peptide 1 (GLP-1) in addictive disorders

Publikation: Bidrag til tidsskriftReviewpeer review

DOI

  1. Advances in migraine and headache therapy (BJP 75th anniversary)

    Publikation: Bidrag til tidsskriftLederpeer review

  2. Metabolic control and sex: A focus on inflammatory-linked mediators

    Publikation: Bidrag til tidsskriftReviewpeer review

  1. Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. SARS-CoV-2 seroprevalence among patients with severe mental illness: A cross-sectional study

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Vis graf over relationer

Drug, alcohol and tobacco use disorders are a global burden affecting millions of people. Despite decades of research, treatment options are sparse or missing, and relapse rates are high. Glucagon-like peptide 1 (GLP-1) is released in the small intestine, promotes blood glucose homeostasis, slows gastric emptying and reduces appetite. GLP-1 receptor agonists approved for treating Type 2 diabetes mellitus and obesity have received attention as a potential anti-addiction treatment. Studies in rodents and non-human primates have demonstrated a reduction in intake of alcohol and drugs of abuse, and clinical trials have been initiated to investigate whether the preclinical findings can be translated to patients. This review will give an overview of current findings and discuss the possible mechanisms of action. We suggest that effects of GLP-1 in alcohol and substance use disorders is mediated centrally, at least partly through dopamine signalling, but precise mechanisms are still to be uncovered. LINKED ARTICLES: This article is part of a themed issue on GLP1 receptor ligands (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.4/issuetoc.

OriginalsprogEngelsk
TidsskriftBritish Journal of Pharmacology
Vol/bind179
Udgave nummer4
Sider (fra-til)625-641
Antal sider17
ISSN0007-1188
DOI
StatusUdgivet - feb. 2022

Bibliografisk note

This article is protected by copyright. All rights reserved.

ID: 69834664